Introduction: Selective monoamine oxidase-B (MAO-B) inhibitors are currently used as coadjuvants for the treatment of early motor symptoms in Parkinson’s disease. They can, based on their chemical structure and mechanism of inhibition, be categorized into reversible and irreversible agents. Areas covered: This review provides a comprehensive update on the development state of selective MAO-B inhibitors describing the results, structures, structure–activity relationships (SARs) and Medicinal chemistry strategies as well as the related shortcomings over the past five years. Expert opinion: Researchers have explored and implemented new and old chemical scaffolds achieving high inhibitory potencies and isoform selectivity. Most of them were characterized and proposed as multitarget agents able to act at different levels (including AChE inhibition, H3R or A2AR antagonism, antioxidant and chelating properties, Aβ1-42 aggregation reduction) in the network of aetiologies of neurodegenerative disorders. These results can also be used to avoid ‘cheese-reaction’ effects and the occurrence of serotonergic syndrome in patients.

Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement? / Guglielmi, P.; Carradori, S.; Ammazzalorso, A.; Secci, D.. - In: EXPERT OPINION ON DRUG DISCOVERY. - ISSN 1746-0441. - 14:10(2019), pp. 995-1035. [10.1080/17460441.2019.1637415]

Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement?

Guglielmi P.
Primo
;
Secci D.
Ultimo
2019

Abstract

Introduction: Selective monoamine oxidase-B (MAO-B) inhibitors are currently used as coadjuvants for the treatment of early motor symptoms in Parkinson’s disease. They can, based on their chemical structure and mechanism of inhibition, be categorized into reversible and irreversible agents. Areas covered: This review provides a comprehensive update on the development state of selective MAO-B inhibitors describing the results, structures, structure–activity relationships (SARs) and Medicinal chemistry strategies as well as the related shortcomings over the past five years. Expert opinion: Researchers have explored and implemented new and old chemical scaffolds achieving high inhibitory potencies and isoform selectivity. Most of them were characterized and proposed as multitarget agents able to act at different levels (including AChE inhibition, H3R or A2AR antagonism, antioxidant and chelating properties, Aβ1-42 aggregation reduction) in the network of aetiologies of neurodegenerative disorders. These results can also be used to avoid ‘cheese-reaction’ effects and the occurrence of serotonergic syndrome in patients.
2019
benzyloxy; coumarins; flavonoids; monoamine oxidase B inhibitors; oxazolidinones; pyrazolines; thiosemicarbazones
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement? / Guglielmi, P.; Carradori, S.; Ammazzalorso, A.; Secci, D.. - In: EXPERT OPINION ON DRUG DISCOVERY. - ISSN 1746-0441. - 14:10(2019), pp. 995-1035. [10.1080/17460441.2019.1637415]
File allegati a questo prodotto
File Dimensione Formato  
Guglielmi_Novel_2019.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 8.16 MB
Formato Adobe PDF
8.16 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1349544
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 43
social impact